From Planning to Living

From Planning to Living

From Planning to Living operates as the personal investment and philanthropic vehicle for Steven Yu, centered on the thesis that the most undervalued asset class is human biology. Rather than following a standard multi-asset family office model, the firm concentrates its intellectual and financial resources exclusively on the longevity economy — a convergence of biotechnology, diagnostics, and health-service delivery designed to compress morbidity and extend healthspan. The investment posture is concentrated, early-stage, and deeply thesis-driven, prioritizing scientific breakthroughs over traditional financial engineering. The firm's deployment strategy is anchored in venture equity across the longevity landscape, spanning therapeutics, digital health platforms, diagnostics, and consumer-focused wellness. Its focus is narrow but deep, targeting areas such as cellular reprogramming, epigenetic clocks, and AI-augmented drug discovery. Confirmed portfolio engagements include early backing of companies like Cambrian Biopharma, a holding company structure developing therapeutics that target the hallmarks of aging, and participation alongside funds like Longevity Vision Fund in companies addressing fundamental mechanisms of aging. The geographic footprint draws from the dense U.S. hubs of San Francisco and Boston, with opportunistic investments in emerging longevity clusters in the U.K. and Switzerland. The firm's scale is that of a concentrated family-risk vehicle rather than a diversified asset manager; it does not disclose total deployment or headcount. Public records indicate that Yu operates through a lean structure with no additional named investment professionals, making direct investment calls from first principles. Adjacent vehicles are not separated into a conventional philanthropic foundation; instead, the line between investment and mission-aligned capital is intentionally blurred — a hallmark of operators who view the entire corpus as dedicated to a single outcome. What structurally differentiates From Planning to Living is its uncompromised mandate. It is not a family office diversifying into longevity as a thematic sleeve, nor a venture fund deploying on behalf of limited partners — it is a single-principal vehicle where the fiduciary duty is to personal conviction. There are no external capital calls, no quarterly redemption pressures, and no competing investment themes. This creates an investment timeline governed by biology, not by fund cycles, allowing the firm to sustain bets on regulatory paths and clinical milestones that institutional funds structurally cannot hold.